| Name | Selinexor (KPT-330) |
| Description | Selinexor (KPT-330) is a small molecule inhibitor of CRM1 with selective and oral activity. Selinexor blocks the cell cycle, induces apoptosis, and has antitumor activity for the treatment of multiple myeloma. |
| In vitro | METHODS: Six T-ALL cells, MOLT-4, Jurkat, HBP-ALL, KOPTK-1, SKW-3 and DND-41, were treated with Selinexor (0-1000 µM) for 72 h. Cell growth inhibition was detected using Cell Titer Glo assay.
RESULTS: Selinexor treatment inhibited T-ALL cell growth with IC50 values of 34-203 nM. [1]
METHODS: Multiple myeloma cells MM1S were treated with Selinexor (100 nM) for 8 h. The expression levels of target proteins were detected by Western Blot.
RESULTS: Selinexor treatment resulted in the accumulation of p53, IκB, p21 and p27 in the nucleus of MM1S cells. [2] |
| In vivo | METHODS: To assay antitumor activity in vivo, Selinexor (20-25 mg/kg) was administered by gavage to NSG mice harboring the human T-ALL tumor MOLT-4 three times per week for thirty-six days.
RESULTS: Selinexor-treated mice exhibited significant inhibition of leukemia cell growth with significant survival benefit. [1]
METHODS: To assay anti-tumor activity in vivo, Selinexor (20 mg/kg) was administered by gavage three times per week for four weeks to an NSG mouse model of primary AML in patients.
RESULTS: Selinexor was cytotoxic to primary AML cells transplanted into mice. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 8.2 mg/mL (18.5 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 38 mg/mL (85.7 mM)
DMSO : 55 mg/mL (124.07 mM)
|
| Keywords | KPT 330 | KPT330 | Selinexor (KPT 330) | Selinexor (KPT330) |
| Inhibitors Related | Leptomycin B | Leptomycin A | CRM1-IN-2 | (E)-KPT330 | Verdinexor | LFS-1107 | KPT276 | CBS9106 | CRM1-IN-1 | KPT185 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library |
United States
